- Pasithea Therapeutics Corp. announced on **November 4, 2025**, the **activation of a new U.S. clinical trial site at the University of Alabama at Birmingham (UAB)** for its ongoing Phase 1/1b open-label study of **PAS-004**.  **[1841330_0001213900-25-105599_ea026382301ex99-1_pasithea.htm:0]** **[1841330_0001213900-25-105599_ea0263823-8k_pasithea.htm:1]** **[1841330_0001213900-25-105599_ea026382301ex99-1_pasithea.htm:1]** 
- The study evaluates **PAS-004**, a next-generation macrocyclic oral MEK inhibitor, in adult patients with **neurofibromatosis type 1 (NF1)** with symptomatic and inoperable, incompletely resected, or recurrent plexiform neurofibromas.  **[1841330_0001213900-25-105599_ea0263823-8k_pasithea.htm:1]** **[1841330_0001213900-25-105599_ea026382301ex99-1_pasithea.htm:1]** 
- Enrollment at the UAB site is expected to **begin immediately**.  **[1841330_0001213900-25-105599_ea0263823-8k_pasithea.htm:1]** **[1841330_0001213900-25-105599_ea026382301ex99-1_pasithea.htm:1]** 
- Pasithea will also serve as **Platinum Sponsor of the 2025 NF Caregivers Symposium** hosted at UAB on **November 8, 2025**.  **[1841330_0001213900-25-105599_ea0263823-8k_pasithea.htm:1]** **[1841330_0001213900-25-105599_ea026382301ex99-1_pasithea.htm:1]**

Pasithea Therapeutics (KTTA)